Opko Health, Inc.

ACTIVE

2110 Research Row, Dallas, Texas, United Stateswww.opko.comPublic3,930 employeesEstablished: 2005-01-01

Also known as:

opko

OPK

opk.us

opko 健康

Clinical Trials

1 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2005

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

42.0%

Phase 1

30.0%

Phase 3

14.0%

Not Applicable

8.0%

Phase 4

2.0%

Trial Status Distribution

Active, not recruiting

2.0%

Completed

74.0%

Recruiting

4.0%

Terminated

16.0%

Withdrawn

4.0%

Clinical Trials

Trials sponsored by this organization (50)

Pharmacokinetics, Pharmacodynamics, Safety and Tolerability Evaluation of CTAP101 Extended-release Capsules in Pediatric Participants

Phase 2

Recruiting

interventional

Aug 202640 participants

Phase 1/2 Study of OPK-88006 in Healthy and Presumed MASH Participants

Phase 1

Recruiting

interventional

Jul 202630 participants

Phase 3 Safety and Efficacy Study of CTAP101 Extended-release Capsules in Children With Secondary Hyperparathyroidism

Phase 3

Terminated

interventional

Jan 20232 participants

Safety and Efficacy of Rayaldee for Treating Mild to Moderate COVID-19

Phase 2

Completed

interventional

Nov 2020171 participants

Quality of Life and Visual Acuity of Visglyc Eye Drops on Dry Eye Patients

Not Applicable

Completed

interventional

May 2019100 participants

A Clinical Study Investigating the Comparability of Somatrogon in Two Different Drug Product Presentations

Phase 1

Completed

interventional

Jan 201949 participants

Pharmacokinetics and Safety Study of CTAP101 Capsules in Japanese and Non-Japanese Healthy Subjects and Non-Japanese Healthy Subjects

Phase 1

Completed

interventional

Aug 201867 participants

Safety, Efficacy, PK and PD of CTAP101 (Calcifediol) ER Capsules for SHPT in HD Patients VDI

Phase 2

Terminated

interventional

Jul 201844 participants

Page 1 of 7

Approvals

No approval data available

News

No news articles found

Back to Organizations